Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027591 | 0.88 | PIK3CD (0.55) | PIK3CDKMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL10572301 | 0.88 | PIK3CD (0.46) | PIK3CDKMT2AALDH1A1KDM4EBRD4 | |
| SCHEMBL13846594 | 0.85 | PIK3CD (0.60) | PIK3CDKMT2AKDM4EBRD4BRD2 | |
| SCHEMBL6888668 | 0.81 | PIK3CD (0.60) | PIK3CDKMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL18226610 | 0.79 | PIK3CD (0.58) | PIK3CDKMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL19158837 | 0.79 | PIK3CD (0.58) | PIK3CDBRD4BRD2PRKAB2PRKAG1 | |
| SCHEMBL4337709 | 0.79 | KMT2A (0.41) | PIK3CDKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL8826885 | 0.79 | P2RX7 (0.38) | PIK3CDKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL1156274 | 0.78 | PIK3CD (0.62) | PIK3CDKMT2AALDH1A1KDM4EBRD4 | |
| SCHEMBL4027588 | 0.78 | PIK3CD (0.56) | PIK3CDBRD4BRD2PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0552360-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-07-28 | — | — | EP | claimed |
| WO-1993003825-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| US-5167941-A | Sulfur dioxide; cationic polyelectrolyte stabilizers | THE DOW CHEMICAL COMPANY (US) | 1992-12-01 | — | — | US | claimed |
| US-5019365-A | Cationic polyelectrolyte | THE DOW CHEMICAL COMPANY (US) | 1991-05-28 | — | — | US | claimed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2020064175-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-08-03 | — | — | US | disclosed |
| US-9670227-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-06-06 | — | — | US | disclosed |
| EP-2886545-B1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2016-06-29 | — | — | EP | disclosed |
| EP-0303501-B1 | SULFUR DIOXIDE REMOVAL FROM GAS STREAMS USING SUBSTITUTED PIPERAZINONES | THE DOW CHEMICAL COMPANY (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5019365-A | Cationic polyelectrolyte | THE DOW CHEMICAL COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| EP-0421794-A2 | Preparation of piperazinones for use as sulfur dioxide absorbents | THE DOW CHEMICAL COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4980471-A | Preparation of piperazinones for use as sulfur dioxide absorbents | THE DOW CHEMICAL COMPANY (US) | 1990-12-25 | — | — | US | disclosed |
| US-4880934-A | Preparation of hydroxyalkylpiperazinones by reacting a 2,3-dihydroxy-1,4-dioxane with a hydroalkyldiamine | THE DOW CHEMICAL COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4814447-A | Preparation of hydroxyalkylpiperazinones by reacting an alkylene oxide with decahydropyrazino[2,3-b]pyrazine or its substituted derivatives | THE DOW CHEMICAL COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4814443-A | Preparation of hydroxyalkylpiperazinones by reacting glyoxal with hydroxyalkyldiamines | THE DOW CHEMICAL COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4783327-A | Sulfur dioxide removal from gas streams using hydroxyalkyl substituted piperazinones | THE DOW CHEMICAL COMPANY (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | PIK3CD 570/4885KMT2A 3050/4885ALDH1A1 2065/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | PIK3CD 1521/4885KMT2A 4824/4885ALDH1A1 638/4885 |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | PIK3CD 570/4885KMT2A 3050/4885ALDH1A1 2065/4885 |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | PIK3CD 570/4885KMT2A 3050/4885ALDH1A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.